Gliomas are primary brain tumors presumably derived from glial cells. The WHO grade IV glioblastoma (GBM), characterized by rapid cell proliferation, easily recrudescent, high morbidity, and mortality, is the most common, devastating, and lethal gliomas. Molecular mechanisms underlying the pathogenesis and progression of GBMs with potential diagnostic and therapeutic value have been explored industriously. With the advent of high-throughput technologies, numerous long noncoding RNAs (lncRNAs) aberrantly expressed in GBMs were discovered recently, some of them probably involved in GBM initiation, malignant progression, relapse and resistant to therapy, or showing diagnostic and prognostic value. In this review, we summarized the profile of lncRNAs that has been extensively investigated in glioma research, with a focus on their regulatory mechanisms. Then, their diagnostic, prognostic, and therapeutic implications were also discussed.
Keyphrases
- high throughput
- high grade
- cell proliferation
- induced apoptosis
- transcription factor
- cell cycle arrest
- multidrug resistant
- network analysis
- genome wide identification
- pi k akt
- neuropathic pain
- endoplasmic reticulum stress
- human health
- stem cells
- free survival
- oxidative stress
- single molecule
- mesenchymal stem cells
- mass spectrometry
- risk assessment
- cell therapy
- quantum dots